AFFX Affymetrix, Inc.

Affymetrix Inc. (NASDAQ:AFFX) today announced that John Batty, executive vice president and chief financial officer, will provide a company overview at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 7th in New York City. A live webcast of the presentation will take place at 8:40 a.m. ET. To access both the live and archived webcasts, please go to www.affymetrix.com and click on the "Investors" link under the �Resources for� dropdown. An archived webcast of the presentation will be available for 30 days. About Affymetrix Affymetrix GeneChip(R) microarray technology is the industry-standard tool for analyzing complex genetic information. After inventing microarray technology in the late 1980s, Affymetrix scientists have been dedicated to developing innovative products that provide researchers with a more complete view of the genome. These products continue to accelerate genetic research and enable scientists to develop diagnostics and tailor treatments for individual patients by identifying and measuring the genetic information associated with complex diseases. Today, Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies, as well as leading academic, government and not-for-profit research institutes. More than 1,600 systems have been shipped around the world and more than 10,600 peer-reviewed papers have been published using the technology. Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Sacramento, Calif., and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit the company's website at www.affymetrix.com. NOTE: Affymetrix, the Affymetrix logo and GeneChip(R) are registered trademarks owned or used by Affymetrix Inc.